Editor’s note: This is the fourth in a six-story series about local companies doing innovative work. Aledade was published on Monday, Precigen was published on Tuesday and Liatris was published on Wednesday.
Company Information
- 20/20 BioLabs Inc. (Nasdaq:AIDX)
- Headquarters: Gaithersburg
- CEO: Jonathan Cohen
- Funded: 2000 (as 20/20 GeneSystems)
- Number of Employees: 24 (13 full time)
- Website: 2020biolabs.com
Jonathan Cohen, 63, of Potomac, says he was a volunteer firefighter and EMT at the Wheaton fire department when he was in college. That work inspired him to enter the field he works in now: cancer testing.
“Firefighters have proven high incidence of death for a variety of cancers,” says Cohen, a lifelong Montgomery County resident who graduated from Woodward High School in North Bethesda and raised his four daughters in the county. Cohen is the founder, president and CEO of 20/20 BioLabs, a biotech company that creates laboratory tests done with samples that customers can collect at home to screen for diseases.
20/20 BioLabs, OneTest product.
20/20 BioLabs, headquartered in Gaithersburg, has 24 employees (13 full time) according to a 2025 Securities and Exchange Commission filing. It has two main products: the OneTest for Cancer, a multi-cancer early detection test (MCED) that screens for more than one type of cancer at the earliest stages of disease, and the OneTest for Longevity, aimed at reducing chronic inflammation and the associated risk of heart disease, cancers and dementia.
Courtesy photo.
20/20 BioLabs provides blood tests that use a patch of microneedles to painlessly collect a sample from capillaries just beneath the skin in the upper arm. 20/20 BioLabs screens those samples—using the same type of automated instruments used in hospitals and big lab chains—for known biomarkers, signals used to monitor for certain health conditions such as inflammation, and for tumor proteins in the case of the cancer test, Cohen says, and supplies customers with a report of the findings. 20/20 is an innovator in applying machine learning, or AI, to this existing technology and knowledge base. “We captured data from parts of the world where these tests are common, applied machine learning and have done validation on American or Western cohorts,” he says. “And by and large, we have seen tremendous equivalency between Western people and people in the East for these biomarkers.”
Cohen says the company’s use of existing blood test platforms in combination with its proprietary analytics
created a faster and less costly pathway to marketing its products and being publicly traded on the stock market. 20/20 BioLabs obtained a direct listing on Nasdaq in February under the ticker AIDX.
The business hasn’t always been focused on its OneTest products. The company was founded in 2000 as 20/20 GeneSystems. Cohen says the first product he helped develop was a kit to screen suspicious powders in response to the 2001 anthrax attacks in the U.S. Cohen says he partnered with the Montgomery County Fire and Rescue Service to use the product. During the COVID-19 pandemic, the company did virus testing for the Montgomery County and the Maryland health departments, Cohen says.
In March, 20/20 BioLabs announced that Maryland fire departments had been awarded more than $520,000 in state funding to procure and administer OneTest cancer screenings through the Maryland Professional and Volunteer Firefighters Innovative Cancer Screening Technologies Program, which provides grants to fire departments for cancer screenings, which are not typically covered by insurance or included in routine physicals.
For a June interview, Cohen was waiting to board a flight for a two week trip to Asia. Cohen’s plan was to meet with collaborators from companies in Taiwan, Japan and South Korea where blood test screenings are more common. He’s hoping to respond quickly to federal legislation passed in early February that will allow Medicare to cover FDA-approved MCEDs, enabling older adults on Medicare to take an approved test once every 11 months beginning in 2028.
20/20 BioLabs has not yet received FDA approval for its tests, but Cohen says it is working to gain FDA approval for the OneTest for Cancer so that it can be covered by Medicare under the legislation.
“We continue to innovate and we’re moving forward with new algorithms that look at biomarker trajectory or
changes over time. Very often, the best way to detect cancer early is by looking at the change not the single time
point,” Cohen says.
This appears in the September/October 2026 issue of Bethesda Magazine.